Skip to main content
All lobbying filings

CAPITOL COUNSEL LLC

Lobbying for GENENTECH

 Filing 2nd Quarter - Report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Income
$70,000.00
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 1
  • CHARLES PATRICK MICHAELS New on this filing
    Previously held: Chief of Staff, Deputy Chief of Staff, Legislative Director, Senior Legislative Assistant, and Legislative Assistant, Rep. David Schweikert; Staff Assistant, Rep. Ted Budd; Intern, Senator James DeMint.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Lobbying activity 2
Medicare/Medicaid

Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.

Health Issues

340B Program issues and patient access to pharmaceuticals. Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy. Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains. Enhanced FDA reporting and risk mitigation plans for certain medicines. Incentives for antimicrobial and antiviral research, medical countermeasures, and novel product development.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem